- Home
- Applications
- united kingdom
- biomarker
Show results for
Refine by
Biomarker Product Applications In United Kingdom
6 applications found
Discover autoantigens in autoimmune diseases, delineate new candidate biomarkers. Autoantibodies are present in the blood of all healthy individuals. However, when directed at high levels against protein targets in specific tissues, autoantibodies can be a major cause of autoimmune diseases. They are also important biomarkers for diagnosis of these conditions. ...
ByCambridge Protein Arrays Ltd. (CPAP) based in Cambridge, UNITED KINGDOM
Microbiotica is using best-in-class clinical data and sample sets coupled with its unrivalled microbiome profiling capability to progress best-in-class therapeutics and biomarkers. Microbiotica has programs in IBD, Immuno-oncology and Gut Epithelial Barrier Repair developing medicines and biomarkers based on microbiota. ...
ByMicrobiotica Limited based in Little Chesterford, UNITED KINGDOM
Kirkstall’s Quasi Vivo® system aims to establish and optimise a human in vitro 3D Blood Brain Barrier (BBB) in an effort to identify important mechanistic pathways for successful biomarker analysis, drug delivery and toxicity ...
ByKirkstall Ltd. based in York, UNITED KINGDOM
Colorectal cancer (CRC) is the third most common cancer all over the world. About 1.8 million new CRC cases were diagnosed globally in 2018, mostly in developed countries. The incidence of colorectal cancer is increasing in line with the ageing population. Early detection is key to successful treatment of the disease and related cost management. An efficient screening strategy is essential to detect the disease early, when it often does not produce symptoms. The currently available faecal occult blood test (FOBT) ...
ByDiagNodus Ltd. based in Cambridge, UNITED KINGDOM
Avoid subjective, empirically and time consuming KT/v calculations / assessments & dry weight assessments. BioScan touch i8 can provide qualitative information for assessing volume status. Over estimation of Dry Weight with subsequent poor blood pressure control impairs the survival and quality of life of HD patients. Expansion of extracellular volume has been associated with hypertension, left ventricular hypertrophy and a higher mortality rate. Likewise, underestimation of Dry Weight results in episodes of ...
ByMaltron International Ltd based in Rayleigh, UNITED KINGDOM
The Optimal Assessment of Volume Status is Vital in the Early Management of Patients. Inadequate assessment can result in not providing necessary treatment or in the administration of unneeded therapy, both associated with increased mortality. Re-imagine the way you see, experience and interact with your patient. See your patient’s physiologic status and trend analysis with exceptional clarity, which you can effortlessly navigate with a simple to use ...
ByMaltron International Ltd based in Rayleigh, UNITED KINGDOM